Using the alternative ELISPOT technique, disclosing both specific CD4 and CD8 cells, there was a striking difference in EBV-specific immune recovery between patients transplanted with myeloablative (MAC) and RIC, suggesting a negative impact of the latter on the risk of developing PTLD (107). Here, CD8A is linked to post-transplant lymphoproliferative disease.